Data / Drug companies / Nivagen Pharmaceuticals, Inc.
Nivagen Pharmaceuticals, Inc.: 61 products in the FDA NDC directory, labeler code 75834
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Nivagen Pharmaceuticals, Inc. (labeler code 75834) lists 61 products in the FDA National Drug Code Directory, covering 24 finished drugs by generic name. By type: 59 prescription drugs, 2 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on December 15, 2025.
The request: Watch Nivagen Pharmaceuticals, Inc. (FDA labeler code 75834): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 75834
- Products in commercial distribution
- 61
- Packages
- 122
- Finished drugs by generic name
- 24
- Prescription products
- 59
- Over the counter products
- 2
- Controlled substance products
- Schedule II 5
- Flagged as original packager
- 40 of 40 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- May 10, 2018
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 48 | 78.7% |
| Other unapproved drugs | 11 | 18% |
| Over the counter monograph drugs | 2 | 3.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 59 | 96.7% |
| Over the counter drugs | 2 | 3.3% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 24 | 39.3% |
| Capsule | 11 | 18% |
| Tablet, film coated | 5 | 8.2% |
| Injection | 4 | 6.6% |
| Tablet, film coated, extended release | 3 | 4.9% |
| Tablet, extended release | 3 | 4.9% |
| Suspension | 2 | 3.3% |
| Tablet, delayed release | 2 | 3.3% |
| Cream | 2 | 3.3% |
| Suppository | 1 | 1.6% |
| Injection, powder, lyophilized, for solution | 1 | 1.6% |
| Ointment | 1 | 1.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Diclofenac potassium | 75834-338 | Powder, for solution | Generic drugs (ANDA) | December 15, 2025 |
| Diclofenac Potassium | 75834-337 | Tablet, film coated | Generic drugs (ANDA) | October 10, 2025 |
| Lidocaine | 75834-333 | Cream | Over the counter monograph drugs | January 5, 2025 |
| Dexmethylphenidate hydrochloride | 75834-328 | Tablet | Generic drugs (ANDA) | May 3, 2024 |
| Dexmethylphenidate hydrochloride | 75834-327 | Tablet | Generic drugs (ANDA) | May 3, 2024 |
| Methylphenidate hydrochloride | 75834-326 | Tablet | Generic drugs (ANDA) | April 16, 2024 |
| Methylphenidate hydrochloride | 75834-325 | Tablet | Generic drugs (ANDA) | April 16, 2024 |
| Methylphenidate hydrochloride | 75834-324 | Tablet | Generic drugs (ANDA) | April 16, 2024 |
| Calcium Acetate | 75834-323 | Capsule | Generic drugs (ANDA) | December 7, 2023 |
| Niva Thyroid | 75834-317 | Tablet | Other unapproved drugs | July 24, 2023 |
| Niva Thyroid | 75834-316 | Tablet | Other unapproved drugs | July 24, 2023 |
| Niva Thyroid | 75834-315 | Tablet | Other unapproved drugs | July 24, 2023 |
| Niva Thyroid | 75834-314 | Tablet | Other unapproved drugs | July 24, 2023 |
| Niva Thyroid | 75834-313 | Tablet | Other unapproved drugs | July 24, 2023 |
| Niva Thyroid | 75834-312 | Tablet | Other unapproved drugs | July 24, 2023 |
| Niva Thyroid | 75834-311 | Tablet | Other unapproved drugs | July 24, 2023 |
| Niva Thyroid | 75834-310 | Tablet | Other unapproved drugs | July 24, 2023 |
| Erythromycin Ethylsuccinate | 75834-295 | Suspension | Generic drugs (ANDA) | February 1, 2023 |
| Erythromycin Ethylsuccinate | 75834-294 | Suspension | Generic drugs (ANDA) | February 1, 2023 |
| Verapamil hydrochloride | 75834-320 | Tablet, film coated, extended release | Generic drugs (ANDA) | January 2, 2023 |
| Hydroquinone 4% | 75834-137 | Cream | Other unapproved drugs | August 17, 2022 |
| Potassium iodide | 75834-280 | Solution | Other unapproved drugs | December 29, 2021 |
| Temozolomide | 75834-146 | Capsule | Generic drugs (ANDA) | December 7, 2021 |
| Temozolomide | 75834-145 | Capsule | Generic drugs (ANDA) | December 7, 2021 |
| Temozolomide | 75834-144 | Capsule | Generic drugs (ANDA) | December 7, 2021 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.